title: [Treatment of uremic patients at high bleeding risk].
authors.affiliation: Department of Internal Medicine, Showa University, Fujigaoka Hospital.
authors.forename: E
authors.initials: E
authors.lastname: Kinugasa
authors.forename: T
authors.initials: T
authors.lastname: Makita
authors.forename: T
authors.initials: T
authors.lastname: Akizawa
authors.forename: S
authors.initials: S
authors.lastname: Koshikawa
mesh_terms: D001550:Benzamidines; D001803:Blood Transfusion; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage; D016670:Gabexate / Q000008:administration & dosage; D006146:Guanidines / Q000008:administration & dosage; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008970:Molecular Weight; D011480:Protease Inhibitors / Q000008:administration & dosage; D006435:Renal Dialysis / Q000009:adverse effects*; D014511:Uremia / Q000209:etiology / Q000628:therapy*
chemical_list: D001550:Benzamidines; D006146:Guanidines; D011480:Protease Inhibitors; D016670:Gabexate; D006493:Heparin; D003894:Deamino Arginine Vasopressin; C032855:nafamostat